GBS
+1
Time Frame for GBS Screening
Sponsored by Rambam Health Care Campus
About this trial
Last updated 4 years ago
Study ID
0251-19-RMB
Status
Withdrawn
Type
Observational
Placebo
No
Accepting
18 to 45 Years
Female
Trial Timing
Ended 2 years ago
What is this trial about?
All pregnant women prenatally being followed up or admitted at Rambam HealthCare Campus, Haifa, Israel are potential participants in the study. If a patient is agreeable, the nurse/physician/research coordinator will obtain informed consent.
Once informed consent is obtained, the patient can be swabbed for GBS. The swabs will be obtained at the routine follow-up at the clinic at 30, 32 and 35 weeks' gestation.
If a patient is found to have a positive GBS culture at 35 weeks, she will receive antibiotic treatment during labour according to the protocol.
GBS swabs taken at delivery will be compared to previous swabs taken at an earlier gestational age in order to evaluate sensitivity, specificity, positive and negative predictive values of GBS swabs at each week of gestation and to determine the value of our primary hypothesis.
What are the participation requirements?
Inclusion Criteria
1. Pregnant women that are being followed up prenatally or admitted at Rambam HealthCare Campus, Haifa, Israel and are planning to deliver there.
2. Women at gestational age 300/7 or less.
Exclusion Criteria
1. Age 18 and under.
2. Women with previous delivery of an infant affected by GBS disease.
3. Women with known bacteriuria in the current pregnancy.
4. Women whom are planning not to deliver at Rambam HealthCare Campus.
5. Women who will not consent to participate in the study.